Published in Hepatitis Weekly, March 1st, 2004
"Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART)," scientists in England noted. "In HIV-negative patients, HBV chronicity is associated with a reduction in specific T-cell responses that can be partially restored by treatment with lamivudine."
R.M. Lascar and colleagues at University College in London examined a group of five "HIV/HBV-coinfected patients treated with HAART, either with or without addition of a drug with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.